Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean angelica sinensis root and ginger and glyceryl and tocopheral?
Displaying drugs 14101 - 14125 of 14836 in total

4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide

Experimental

N,N'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE

Experimental

6-amino-2-[(thiophen-2-ylmethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one

Experimental

SP-8203

SP-8203 has been used in trials studying the treatment of Ischemic Stroke.
Investigational

GDC-0349

GDC-0349 has been used in trials studying the treatment of Non-Hodgkin's Lymphoma, Solid Tumor.
Investigational

IQP-0528

IQP-0528 is under investigation in clinical trial NCT03082690 (ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study).
Investigational

AZD3409

AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004. As of February 2007 the development of AZD3409 had been discontinued.
Investigational
Matched Description: … Phase I trials were initiated January 2003, and were ongoing as of February 2004. …

Seproxetine

Seproxetine is also known as (S)-norfluoxetine. It is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.
Investigational
Matched Description: … Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and …

Giredestrant

Giredestrant is under investigation in clinical trial NCT06065748 (A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With Er-positive, Her2-negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (Pionera Breast Cancer)).
Investigational
Matched Description: … Giredestrant is under investigation in clinical trial NCT06065748 (A Study to Evaluate Efficacy and Safety …

2,4-Diamino-5-Methyl-6-[(3,4,5-Trimethoxy-N-Methylanilino)Methyl]Pyrido[2,3-D]Pyrimidine

Experimental

CRA_1144

Experimental

Methyl-[4-(4-Piperidine-1-Ylmethyl-Phenyl)-Cyclohexyl]-Carbaminic Acid-(4-Chlorophenyl)-Ester

Experimental

2-(2,6-DICHLOROPHENYL)-1,3-BENZOXAZOLE-6-CARBOXYLIC ACID

Experimental

(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-[(R)-HYDROXY{(1R)-2-METHYL-1-[(PHENYLSULFONYL)AMINO]PROPYL}PHOSPHORYL]PROPANOIC ACID

Experimental

N-[amino(imino)methyl]-2-[2-(2-chlorophenyl)-4-(4-propoxyphenyl)-3-thienyl]acetamide

Experimental

(2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE

Experimental

N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine

Experimental

p-Nitrophenylacetic acid

Experimental

4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE

Experimental

N-oxo-2-(phenylsulfonylamino)ethanamide

Experimental

2-(3-NITROPHENYL)ACETIC ACID

Experimental

N-(3-AMINOPROPYL)-2-NITROBENZENAMINE

Experimental

Pumosetrag

Pumosetrag has been used in trials studying Gastroesophageal Reflux Disease.
Investigational

123I-iodometomidate

123I-iodometomidate is under investigation in clinical trial NCT00454103 (Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy).
Investigational

SR 121463

SR 121463 is a nonpeptide aquaretic compound with potent selective antagonism of the vasopressin V2 (V1b) receptor subtype. It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH).
Investigational
Matched Description: … It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion …
Displaying drugs 14101 - 14125 of 14836 in total